TD has acquired Cowen Inc. Please bookmark TD Securities for further updates.

Liquid Biopsy Summit

TD Cowen issued its first report on liquid biopsy ten years ago. In it, we introduced the concept, highlighted the early entrants, and evaluated the opportunity. Today, commercial traction (in particular for oncology) is material with a handful of players (mostly public) dominating. Additionally, many new companies are expected to enter leveraging new innovation & strategies. 

What will the next 10+ years look like?  Please join the TD Cowen team and an array of liquid biopsy leaders and innovators for a one-day summit to answer that question.

*Cowen conferences and events are intended for institutional clients and corporate clients of the firm. They are not open to media or retail investors.

Related Insights

Robotic arm holding out a generic pill bottle.

AI Designing Drugs: Navigating the Hype

Two pharmacists checking products on their shelves.

The Evolving Landscape Of Pharmacy Reimbursement

Woman has her hand on a prescription bottle of medication behind the counter in a pharmacy.
Ahead of the Curve®

Drug Pricing Survey Again Suggests Positive Outlook